Prelude Therapeutics Incorporated
PRLDHealthcare|Biotechnology|US
$3.60
+0.04 (+1.27%)
DCF Value
$3.79
Tangible Book / Share
$1.36
Cash / Share
$1.54
Clinical Trials (13)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07469891 A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms | Polycythemia Vera (PV), Myelofibrosis (MF) | P1 | Recruiting | 100 | Open-label | PRT12396 |
| NCT06682806 A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | Advanced Solid Tumor, Esophageal Cancer | P2 | Terminated | 6 | Open-label | PRT3789, pembrolizumab |
| NCT05159518 A Study of PRT2527 in Participants With Advanced Solid Tumors | Sarcoma, Castrate Resistant Prostate Cancer | P1 | Completed | 30 | Open-label | PRT2527 |
| NCT05665530 A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | P1 | Completed | 86 | Open-label | PRT2527, Zanubrutinib, Venetoclax |
| NCT05107856 PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma | P1 | Terminated | 21 | Open-label | PRT1419, Azacitidine, Venetoclax |
| NCT03886831 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies | Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma | P1 | Completed | 232 | Open-label | PRT543 |
| NCT05639751 PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | Advanced Solid Tumor, Metastatic Solid Tumor | P1 | Completed | 135 | Open-label | PRT3789, Docetaxel |
| NCT04089449 A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas | Advanced Solid Tumor, Recurrent Glioma | P1 | Completed | 86 | Open-label | PRT811 |
| NCT06560645 A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | Advanced Solid Tumor, Metastatic Solid Tumor | P1 | Terminated | 42 | Open-label | PRT7732 |
| NCT04837677 A Study of PRT1419 in Patients With Advanced Solid Tumors | Sarcoma, Melanoma | P1 | Completed | 26 | Open-label | PRT1419 |
| NCT07905001 A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer | Breast Cancer, Hormone-receptor-positive Breast Cancer | P1 | Not Yet Recruiting | 242 | Open-label | PRT13722, Fulvestrant, Abemaciclib, Imlunestrant |
| NCT05538572 A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Breast Cancer, Glioblastoma | P1 | Completed | 22 | Open-label | PRT3645 |
| NCT04543305 A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | Multiple Myeloma, Acute Myeloid Leukemia | P1 | Completed | 16 | Open-label | PRT1419 |